Asarina Pharma AB publishes prospectus in connection with share issue of SEK 142,8M and listing on Nasdaq First North
The Board of Asarina Pharma AB (“Asarina Pharma” or the “Company”) has resolved on a share issue of up to 6,800,000 shares and has decided to apply for admission to trading of the Company’s share on Nasdaq First North. The subscription price amounts to SEK 21 per share, which corresponds to an issue amount of no more than SEK 142,8M (the “Offer”). Based on the subscription price and existing number of shares, the Company is valued at approximately SEK 172M. In the Offer, a number of institutional and private investors, including Sectoral Asset Management, Swedbank Robur, Östersjöstiftelsen,